PmrB mutations promote polymyxin resistance of Pseudomonas aeruginosa isolated from colistin-treated cystic fibrosis patients

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 2, 2012, Pages 1019-1030

  Moskowitz, Samuel M ^a,b,c   Brannon, Mark K ^c   Dasgupta, Nandini ^a   Pier, Miyuki ^c,f   Sgambati, Nicole ^a   Miller, Amanda K ^c,g   Selgrade, Sara E ^c,h   Miller, Samuel I ^c   Denton, Miles ^d   Conway, Steven P ^d   Johansen, Helle K ^e   Høiby, Niels ^e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f PUGET SOUND BLOOD CENTER   (United States)

^g AMGEN INC   (United States)

^h NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID LIPASE; COLISTIN; PHOSPHOTRANSFERASE; POLYMYXIN;

ALLELE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CYSTIC FIBROSIS; DIMERIZATION; DRUG RESISTANCE; GENE; GENE DELETION; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENETIC TRANSCRIPTION; MINIMUM INHIBITORY CONCENTRATION; MUTANT; NUCLEOTIDE SEQUENCE; OPERON; PHENOTYPE; PMRB GENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN MODIFICATION; PSEUDOMONAS AERUGINOSA; WILD TYPE;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; COLISTIN; CYSTIC FIBROSIS; DRUG RESISTANCE, BACTERIAL; GENE EXPRESSION REGULATION, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; POLYMYXINS; PSEUDOMONAS AERUGINOSA; TRANSCRIPTION FACTORS;

EID: 84863393429     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05829-11     Document Type: Article

References (60)

1. Abraham N, Kwon DH. 2009. A single amino acid substitution in PmrB is associated with polymyxin B resistance in clinical isolate of Pseudomonas aeruginosa. FEMS Microbiol. Lett. 298:249-254.
2. Adams MD, et al. 2009. Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob. Agents Chemother. 53:3628-3634.
3. Alonso A, Campanario E, Martinez JL. 1999. Emergence of multidrug-resistant mutants is increased under antibiotic selective pressure in Pseudomonas aeruginosa. Microbiology 145:2857-2862. (Pubitemid 29485900)
4. Antoine R, Locht C. 1992. Isolation and molecular characterization of a novel broad-host-range plasmid from Bordetella bronchiseptica with sequence similarities to plasmids from gram-positive organisms. Mol. Microbiol. 6:1785-1799.
5. Barrow K, Kwon DH. 2009. Alterations in two-component regulatory systems of phoPQ and pmrAB are associated with polymyxin B resistance in clinical isolates of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 53:5150-5154.
6. Boll M, Radziejewska-Lebrecht J, Warth C, Krajewska-Pietrasik D, Mayer H. 1994. 4-Amino-4-deoxy-L-arabinose in LPS of enterobacterial R-mutants and its possible role for their polymyxin reactivity. FEMS Immunol. Med. Microbiol. 8:329-341. (Pubitemid 24161795)
7. Brannon MK, et al. 2005. Colistin-treated cystic fibrosis patients harbor polymyxin-resistant strains of Pseudomonas aeruginosa, some with mutation of PmrAB, a two-component regulator of lipid A structure. Pediatr. Pulmonol. Suppl. 28:289.
8. Caroff M, Tacken A, Szabo L. 1988. Detergent-accelerated hydrolysis of bacterial endotoxins and determination of the anomeric configuration of the glycosyl phosphate present in the "isolated lipid A" fragment of the Bordetella pertussis endotoxin. Carbohydr. Res. 175:273-282.
9. Choi KH, Kumar A, Schweizer HP. 2006. A 10-min method for preparation of highly electrocompetent Pseudomonas aeruginosa cells: application for DNA fragment transfer between chromosomes and plasmid transformation. J. Microbiol. Methods 64:391-397. (Pubitemid 43212814)
10. Ciofu O, Giwercman B, Pedersen SS, Høiby N. 1994. Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish CF Center. APMIS 102:674-680. (Pubitemid 24355375)
11. Clinical Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 7th ed. M7-A7. CLSI, Wayne, PA.
12. Curran B, Jonas D, Grundmann H, Pitt T, Dowson CG. 2004. Development of a multilocus sequence typing scheme for the opportunistic pathogen Pseudomonas aeruginosa. J. Clin. Microbiol. 42:5644-5649. (Pubitemid 39664348)
13. Darveau RP, Hancock RE. 1983. Procedure for isolation of bacterial lipopolysaccharides from both smooth and rough Pseudomonas aeruginosa and Salmonella typhimurium strains. J. Bacteriol. 155:831-838. (Pubitemid 13048117)
14. Denton M, et al. 2002. Transmission of colistin-resistant Pseudomonas aeruginosa between patients attending a pediatric cystic fibrosis center. Pediatr. Pulmonol. 34:257-261.
15. Ernst RK, et al. 1999. Specific lipopolysaccharide found in cystic fibrosis airway Pseudomonas aeruginosa. Science 286:1561-1565.
16. Falagas ME, Bliziotis IA. 2007. Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era? Int. J. Antimicrob. Agents 29:630-636. (Pubitemid 46710354)
17. Foweraker JE, Laughton CR, Brown DF, Bilton D. 2009. Comparison of methods to test antibiotic combinations against heterogeneous populations of multiresistant Pseudomonas aeruginosa from patients with acute infective exacerbations in cystic fibrosis. Antimicrob. Agents Chemother. 53:4809-4815.
18. Frederiksen B, Koch C, Høiby N. 1997. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr. Pulmonol. 23:330-335. (Pubitemid 27225208)
19. Frederiksen B, Lanng S, Koch C, Høiby N. 1996. Improved survival in the Danish center-treated cystic fibrosis patients: results of aggressive treatment. Pediatr. Pulmonol. 21:153-158. (Pubitemid 26127307)
20. Giwercman B, Lambert PA, Rosdahl VT, Shand GH, Høiby N. 1990. Rapid emergence of resistance in Pseudomonas aeruginosa in cystic fibrosis patients due to in-vivo selection of stable partially derepressed betalactamase producing strains. J. Antimicrob. Chemother. 26:247-259. (Pubitemid 20266021)
21. Gunn JS, et al. 1998. PmrA-PmrB-regulated genes necessary for 4-aminoarabinose lipid A modification and polymyxin resistance. Mol. Microbiol. 27:1171-1182. (Pubitemid 28137969)
22. Gunn JS, Ryan SS, Van Velkinburgh JC, Ernst RK, Miller SI. 2000. Genetic and functional analysis of a PmrA-PmrB-regulated locus necessary for lipopolysaccharide modification, antimicrobial peptide resistance, and oral virulence of Salmonella enterica serovar Typhimurium. Infect. Immun. 68:6139-6146.
23. Hawley JS, Murray CK, Jorgensen JH. 2008. Colistin heteroresistance in Acinetobacter and its association with previous colistin therapy. Antimicrob. Agents Chemother. 52:351-352.
24. Henrichfreise B, Wiegand I, Pfister W, Wiedemann B. 2007. Resistance mechanisms of multiresistant Pseudomonas aeruginosa strains from Germany and correlation with hypermutation. Antimicrob. Agents Chemother. 51:4062-4070. (Pubitemid 350057805)
25. Ho SN, Horton RM. June 1991. Method for gene splicing by overlap extension using the polymerase chain reaction. US patent 5023171.
26. Hoang TT, Karkhoff-Schweizer RR, Kutchma AJ, Schweizer HP. 1998. A broad-host-range Flp-FRT recombination system for site-specific excision of chromosomally-located DNA sequences: application for isolation of unmarked Pseudomonas aeruginosa mutants. Gene 212:77-86. (Pubitemid 28269135)
27. Hoang TT, Kutchma AJ, Becher A, Schweizer HP. 2000. Integrationproficient plasmids for Pseudomonas aeruginosa: site-specific integration and use for engineering of reporter and expression strains. Plasmid 43:59-72. (Pubitemid 30049004)
28. Jensen T, et al. 1987. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J. Antimicrob. Chemother. 19:831-838. (Pubitemid 17092071)
29. Johansen HK, Moskowitz SM, Ciofu O, Pressler T, Høiby N. 2008. Spread of colistin resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients. J. Cyst. Fibros. 7:391-397.
30. Knowles MR, Boucher RC. 2002. Mucus clearance as a primary innate defense mechanism for mammalian airways. J. Clin. Invest. 109:571-577. (Pubitemid 34204834)
31. Kulasekara HD, et al. 2005. A novel two-component system controls the expression of Pseudomonas aeruginosa fimbrial cup genes. Mol. Microbiol. 55:368-380. (Pubitemid 40179374)
32. Letunic I, Doerks T, Bork P. 2009. SMART 6: recent updates and new developments. Nucleic Acids Res. 37:D229-D232.
33. Li J, et al. 2006. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 50:2946-2950. (Pubitemid 44396396)
34. Lyczak JB, Cannon CL, Pier GB. 2000. Establishment of Pseudomonas aeruginosa infection: lessons from a versatile opportunist. Microbes Infect. 2:1051-1060. (Pubitemid 30664219)
35. Macfarlane EL, Kwasnicka A, Hancock RE. 2000. Role of Pseudomonas aeruginosa PhoP-PhoQ in resistance to antimicrobial cationic peptides and aminoglycosides. Microbiology 146:2543-2554.
36. Macfarlane EL, Kwasnicka A, Ochs MM, Hancock RE. 1999. PhoPPhoQ homologues in Pseudomonas aeruginosa regulate expression of the outer-membrane protein OprH and polymyxin B resistance. Mol. Microbiol. 34:305-316. (Pubitemid 29486248)
37. Mahenthiralingam E, Campbell ME, Speert DP. 1994. Nonmotility and phagocytic resistance of Pseudomonas aeruginosa isolates from chronically colonized patients with cystic fibrosis. Infect. Immun. 62:596-605. (Pubitemid 24033780)
38. McPhee JB, Lewenza S, Hancock RE. 2003. Cationic antimicrobial peptides activate a two-component regulatory system, PmrA-PmrB, that regulates resistance to polymyxin B and cationic antimicrobial peptides in Pseudomonas aeruginosa. Mol. Microbiol. 50:205-217. (Pubitemid 37222798)
39. Miller AK, et al. 2011. PhoQ mutations promote lipid A modification and polymyxin resistance of Pseudomonas aeruginosa found in colistin-treated cystic fibrosis patients. Antimicrob. Agents Chemother. 55:5761-5769.
40. Moskowitz SM, et al. 2000. Polymyxin resistance and lipid A structure of Pseudomonas aeruginosa isolated from colistin-treated and colistin-naïve cystic fibrosis patients. Pediatr. Pulmonol. Suppl. 20:272.
41. Moskowitz SM, Ernst RK. 2010. The role of Pseudomonas lipopolysaccharide in cystic fibrosis airway infection. Subcell. Biochem. 53:241-253.
42. Moskowitz SM, Ernst RK, Miller SI. 2004. PmrAB, a two-component regulatory system of Pseudomonas aeruginosa that modulates resistance to cationic antimicrobial peptides and addition of aminoarabinose to lipid A. J. Bacteriol. 186:575-579. (Pubitemid 38076447)
43. Moskowitz SM, et al. 2008. Shifting patterns of inhaled antibiotic use in cystic fibrosis. Pediatr. Pulmonol. 43:874-881.
44. Newman JR, Fuqua C. 1999. Broad-host-range expression vectors that carry the L-arabinose-inducible Escherichia coli araBAD promoter and the araC regulator. Gene 227:197-203. (Pubitemid 29104855)
45. Nummila K, Kilpelainen I, Zahringer U, Vaara M, Helander IM. 1995. Lipopolysaccharides of polymyxin B-resistant mutants of Escherichia coli are extensively substituted by 2-aminoethyl pyrophosphate and contain aminoarabinose in lipid A. Mol. Microbiol. 16:271-278.
46. Pedersen SS, Koch C, Høiby N, Rosendal K. 1986. An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre. J. Antimicrob. Chemother. 17:505-516. (Pubitemid 16143216)
47. Pedersen SS, et al. 1987. Combined imipenem/cilastatin and tobramycin therapy of multiresistant Pseudomonas aeruginosa in cystic fibrosis. J. Antimicrob. Chemother. 19:101-107. (Pubitemid 17234586)
48. Permin H, et al. 1983. Ceftazidime treatment of chronic Pseudomonas aeruginosa respiratory tract infection in cystic fibrosis. J. Antimicrob. Chemother. 12(Suppl A):313-323. (Pubitemid 13001005)
49. Pioszak AA, Ninfa AJ. 2003. Mechanism of the PII-activated phosphatase activity of Escherichia coli NRII (NtrB): how the different domains of NRII collaborate to act as a phosphatase. Biochemistry 42:8885-8899. (Pubitemid 36899833)
50. Roland KL, Martin LE, Esther CR, Spitznagel JK. 1993. Spontaneous pmrA mutants of Salmonella typhimurium LT2 define a new twocomponent regulatory system with a possible role in virulence. J. Bacteriol. 175:4154-4164. (Pubitemid 23206910)
51. Schurek KN, et al. 2009. Involvement of pmrAB and phoPQ in polymyxin B adaptation and inducible resistance in non-cystic fibrosis clinical isolates of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 53:4345-4351.
52. Storm DR, Rosenthal KS, Swanson PE. 1977. Polymyxin and related peptide antibiotics. Annu. Rev. Biochem. 46:723-763. (Pubitemid 8252143)
53. Szaff M, Høiby N, Flensborg EW. 1983. Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. Acta Paediatr. Scand. 72:651-657. (Pubitemid 13048784)
54. Tenover FC, et al. 1995. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J. Clin. Microbiol. 33:2233-2239.
55. Trent MS, et al. 2001. Accumulation of a polyisoprene-linked amino sugar in polymyxin-resistant Salmonella typhimurium and Escherichia coli: structural characterization and transfer to lipid A in the periplasm. J. Biol. Chem. 276:43132-43144.
56. Valerius NH, Koch C, Høiby N. 1991. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 338:725-726.
57. Winsor GL, et al. 2009. Pseudomonas Genome Database: facilitating user-friendly, comprehensive comparisons of microbial genomes. Nucleic Acids Res. 37:D483-D488.
58. Wolfgang MC, Lee VT, Gilmore ME, Lory S. 2003. Coordinate regulation of bacterial virulence genes by a novel adenylate cyclase-dependent signaling pathway. Dev. Cell 4:253-263. (Pubitemid 36221801)
59. Woodcock DM, et al. 1989. Quantitative evaluation of Escherichia coli host strains for tolerance to cytosine methylation in plasmid and phage recombinants. Nucleic Acids Res. 17:3469-3478. (Pubitemid 19120446)
60. Yi EC, Hackett M. 2000. Rapid isolation method for lipopolysaccharide and lipid A from gram-negative bacteria. Analyst 125:651-656. (Pubitemid 30223651)